Europeiska unionen - maltesiska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - għall-pazjenti adulti b'dijabete tat-tip 2 mellitus, ristaben huwa indikat biex itejbu l-kontroll gliċemiku:bħala monoterapija:f'pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien mal:metformin meta d-dieta u l-eżerċizzju flimkien ma 'metformin waħdu ma jipprovdux kontroll gliċemiku adegwat;sulphonylurea meta d-dieta u l-eżerċizzju flimkien ma' doża massima tollerata ta ' sulphonylurea waħedhom ma jipprovdux kontroll gliċemiku adegwat u meta metformin ma jkunx adegwat minħabba kontraindikazzjonijiet jew intolleranza;a peroxisome proliferator-activated-riċettur gamma (ppary) agonist (i. thiazolidinedione) meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma 'l-agonist ppary waħdu ma jipprovdux kontroll gliċemiku adegwat;bħala terapija trippla orali f'kombinazzjoni ma': sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat;ppary agonista u metformin meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat. ristaben huwa wkoll indikat bħala żieda mal-insulina (bil-metformina jew mingħajrha) meta d-dieta u l-eżerċizzju flimkien ma doża stabbli ta ' l-insulina ma jipprovdux kontroll gliċemiku adegwat.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - għall-pazjenti adulti b'dijabete tat-tip 2 mellitus, xelevia huwa indikat biex itejbu l-kontroll gliċemiku:bħala monoterapija:f'pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien mal:metformin meta d-dieta u l-eżerċizzju flimkien ma 'metformin waħdu ma jipprovdux kontroll gliċemiku adegwat;sulphonylurea meta d-dieta u l-eżerċizzju flimkien ma' doża massima tollerata ta ' sulphonylurea waħedhom ma jipprovdux kontroll gliċemiku adegwat u meta metformin ma jkunx adegwat minħabba kontraindikazzjonijiet jew intolleranza;a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. thiazolidinedione) meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma 'l-agonist ppary waħdu ma jipprovdux kontroll gliċemiku adegwat;bħala terapija trippla orali f'kombinazzjoni ma': sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat;ppary agonista u metformin meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat. xelevia huwa wkoll indikat bħala żieda mal-insulina (bil-metformina jew mingħajrha) meta d-dieta u l-eżerċizzju flimkien ma doża stabbli ta ' l-insulina ma jipprovdux kontroll gliċemiku adegwat.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - għall-pazjenti b'dijabete tat-tip 2 mellitus, tesavel huwa indikat biex itejbu l-kontroll gliċemiku:bħala monoterapija:f'pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien mal:metformin meta d-dieta u l-eżerċizzju flimkien ma 'metformin waħdu ma jipprovdux kontroll gliċemiku adegwat;sulphonylurea meta d-dieta u l-eżerċizzju flimkien ma' doża massima tollerata ta ' sulphonylurea waħedhom ma jipprovdux kontroll gliċemiku adegwat u meta metformin ma jkunx adegwat minħabba kontraindikazzjonijiet jew intolleranza;a ppary agonist (i. thiazolidinedione) meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma ' l-agonist ppary waħdu ma jipprovdux kontroll gliċemiku adegwat;bħala terapija trippla orali f'kombinazzjoni bi sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn l-aġenti ma jipprovdux kontroll gliċemiku adegwat;peroxisome-proliferator-activated-riċettur gamma (ppary) agonist u metformin meta l-użu ta'l-agonist ppary huwa xieraq u meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn l-aġenti ma jipprovdux kontroll gliċemiku adegwat. tesavel huwa indikat ukoll bħala add-on għall-insulina (bil-metformina jew mingħajrha) meta d-dieta u l-eżerċizzju flimkien ma stabbli fid-dożaġġ ta ' l-insulina ma jipprovdux kontroll gliċemiku adegwat.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - diabetes mellitus, tip 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia huwa indikat fl-adulti l-età ta ' 18-il sena u aktar antiki mal-tip 2 diabetes mellitus biex jitjieb il-kontroll ta ' glycaemic flimkien ma ' oħra tal-glukosju li jitbaxxew il-prodotti mediċinali inklużi l-insulina, meta dawn, flimkien ma ' dieta u l-eżerċizzju, ma jipprovdux adegwata glycaemic kontroll (ara sezzjonijiet 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5.